Skip to main content

Advertisement

SpringerLink
Log in

Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC).

Methods

Patients (N = 18) with 0 or 1 line of prior chemotherapy received oxaliplatin 100 mg/m2 on day 1 from 1400 to 1800 hours with escalating dose levels of capecitabine (2,500, 3,000, 3,500, 4,000, 4,500, and 5,000 mg) once daily taken at 2400 hours on days 1–5. Each cycle lasted 14 days.

Results

The MTD of capecitabine was 4,500 mg. Transaminitis and anemia were the commonest non-hematologic and hematologic toxicities, respectively. Toxicities were generally mild, with only five occurrences of grade 3 toxicity and none of grade 4. There were no dose-limiting toxicities, defined as specific grade 3 or 4 toxicities occurring in the first two cycles of treatment. The objective response rate was 33.3 %, and median overall survival was 16.3 months (95 % CI: 11.2–18.2 months). The maximum plasma concentration (C max) and area under plasma concentration–time curve from time 0 to infinity (AUC[0–∞]) of the capecitabine metabolites in our fixed-dosing chronomodulated regimen were comparable to values seen with comparably dose-intense regimens but associated with significantly reduced toxicity.

Conclusions

Chronomodulated dose-intensified XELOX facilitates delivery of dose-intense treatment in mCRC with a favorable therapeutic index that is promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Poon MA, O’Connell MJ, Wieand HS et al (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9(11):1967–1972

    PubMed  CAS  Google Scholar 

  2. Borner MM, Castiglione M, Bacchi M et al (1998) The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Ann Oncol 9(5):535–541

    Article  PubMed  CAS  Google Scholar 

  3. de Gramont A, Bosset JF, Milan C et al (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15(2):808–815

    PubMed  Google Scholar 

  4. Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16(1):301–308

    Google Scholar 

  5. Lévi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86(21):1608–1617

    Article  PubMed  Google Scholar 

  6. Lévi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350(9079):681–686

    Article  PubMed  Google Scholar 

  7. Lévi F, Zidani R, Brienza S et al (1999) A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 85(12):2532–2540

    Article  PubMed  Google Scholar 

  8. de Gramont A, Vignoud J, Tournigand C et al (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33(2):214–219

    Article  PubMed  Google Scholar 

  9. Giacchetti S, Bjarnason G, Garufi C et al (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22):3562–3569

    Article  PubMed  CAS  Google Scholar 

  10. Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274–1281

    Article  PubMed  CAS  Google Scholar 

  11. Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006–2012

    Article  PubMed  CAS  Google Scholar 

  12. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19(10):1720–1726

    Article  PubMed  CAS  Google Scholar 

  13. O’quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33–48

    Article  PubMed  Google Scholar 

  14. Goodman SN, Zahurak ML, Piantadosi S (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14:1149–1161

    Article  PubMed  CAS  Google Scholar 

  15. Tan SB, Tan SH, Machin D (2005) Early phase clinical trials (EPCT) software. UKCCSG Data Centre, Leicester

    Google Scholar 

  16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  17. Zufía L, Aldaz A, Giráldez J (2004) Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. J Chromatogr B Analyt Technol Biomed Life Sci 809(1):51–58

    Article  PubMed  Google Scholar 

  18. Lévi F, Okyar A, Dulong S et al (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421

    Article  PubMed  Google Scholar 

  19. Levi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593–628

    Article  PubMed  CAS  Google Scholar 

  20. Smaaland R, Laerum OD, Sothern RB et al (1992) Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariation. Blood 79(9):2281–2287

    PubMed  CAS  Google Scholar 

  21. Lévi F, Focan C, Karaboué A et al (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59(9–10):1015–1035

    Article  PubMed  Google Scholar 

  22. Scheithauer W, Kornek GV, Raderer M et al (2002) Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 13(10):1583–1589

    Article  PubMed  CAS  Google Scholar 

  23. Díaz-Rubio E, Evans TR, Tabemero J et al (2002) Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 13(4):558–565

    Article  PubMed  Google Scholar 

  24. Scheithauer W, Kornek GV, Raderer M et al (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21(7):1307–1312

    Article  PubMed  CAS  Google Scholar 

  25. Sharma R, Rivory L, Beale P et al (2006) A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer 94(7):964–968

    Article  PubMed  CAS  Google Scholar 

  26. Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40(2):85–104

    Article  PubMed  CAS  Google Scholar 

  27. Mackean M, Planting A, Twelves C et al (1998) Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16(9):2977–2985

    PubMed  CAS  Google Scholar 

  28. Xeloda Prescribing Information [Drugs@FDA] (2011) Available from web. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf. Accessed 28 Apr 2011

  29. Mulkerin D, LoConte NK, Holen KD et al (2009) A phase I study of an oral simulated FOLFOX with high dose capecitabine. Invest New Drugs 27(5):461–468

    Article  PubMed  CAS  Google Scholar 

  30. Santini D, Vincenzi B, Schiavon G et al (2007) Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 59(5):613–620

    Article  PubMed  CAS  Google Scholar 

  31. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229–237

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Authors are thankful to the National Medical Research Council grant NMRC/0994/2005 for supporting the study and the patients who participated in the study.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore, 169610, Singapore

    Mohamad Farid, Wen Hsin Koo, Han Chong Toh, Su Pin Choo & Simon Yew Kuang Ong

  2. Laboratory of Clinical Pharmacology, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Centre, 11 Hospital Drive, Singapore, 169610, Singapore

    Balram Chowbay, Xiangai Chen & Saminathan Ramasamy

  3. Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre, 11 Hospital Drive, Singapore, 169610, Singapore

    Sze Huey Tan

  4. Centre of Quantitative Medicine, Duke-NUS Graduate Medical School, 8 College Road, Singapore, 169857, Singapore

    Sze Huey Tan

Authors
  1. Mohamad Farid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Balram Chowbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiangai Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sze Huey Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Saminathan Ramasamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen Hsin Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Han Chong Toh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Su Pin Choo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Simon Yew Kuang Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon Yew Kuang Ong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farid, M., Chowbay, B., Chen, X. et al. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol 70, 141–150 (2012). https://doi.org/10.1007/s00280-012-1895-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1895-x

Keywords

Search

Navigation